Big Data EEG-Analysis for Advanced Personalised Medicine in Depression
Sector: Hospital • Location: Israel
Source: EU Funding & Tenders Portal
Modern medicine has given us countless methods of understanding, measuring and managing such metrics of our health as temperature, weight, body fat percentage, cholesterol, PSA values, etc. A patient’s measured values are easily compared against well-established normal ranges. And yet a simple, non-invasive method for measuring and quantifying the health of our brains has eluded us. Being unable t
- Status
- Closed
- Sector
- Hospital
- Location
- Israel
- Updated
- 22 Jul 2026
- Source
- EU Funding & Tenders Portal
ConstructChat
Ask ConstructChat about Big Data EEG-Analysis for Advanced Personalised Medicine in Depression
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
| Not available for this record. |
Status
Original status | ended |
Taiyo status | Closed |
Taiyo last update | 2026-07-22 |
Contact
| Not available for this record. |
Description
Description | Modern medicine has given us countless methods of understanding, measuring and managing such metrics of our health as temperature, weight, body fat percentage, cholesterol, PSA values, etc. A patient’s measured values are easily compared against well-established normal ranges. And yet a simple, non-invasive method for measuring and quantifying the health of our brains has eluded us. Being unable to accurately measure and compare how a brain functions hinders doctors’ ability to diagnose and treat suspected ailments. It also slows the substantiation of new therapies. And, just as importantly, it prevents each of us from truly understanding and taking ownership of the health of our body’s most important organ. Major Depressive Disorder (MDD) has been identified as the leading and most costly mental disorder, accounting for 33% of the total cost of brain disorders, and equal to 1% of the GDP. Each year, about 7% of the population suffer from MDD in Europe, equivalent to 52.98 million people. The current methods of treatment are prescribed through trial and error with patients rarely receiving the ‘right’ treatment from day one. This reduces response rates and delays remission, which has a heavy impact on the individual’s quality of life. elminda has developed the “PREDICT” tool which predicts responsiveness to antidepressants and TMS treatment, and thus dramatically reduces time from diagnosis to amelioration of symptoms for MDD patients. PREDICT determines personalised treatments for MDD patients based on validated electroencephalogram and event-related potential brain-related biomarkers. The tool predicts responsiveness to antidepressants and TMS treatment, and thus dramatically reduces time from diagnosis to amelioration of symptoms. This improves response rates, quality of life and results in significant savings for the healthcare systems. |
Location
Country | Israel |
Source
Source | EU Funding & Tenders Portal |
URL |
More Details
Record type | Project |
Sector | Hospital |
Article published date | 2026-02-01 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
More Hospital projects in Israel
- SOREK II DESALINATION PLANT
- New Performances for Mediterranean Tourism
- Life Saving Technology for Thoracic Trauma Treatment and Post Operative Drainage
- Sorrel Medical’s New Manufacturing Facility, Netanya
- MRI Designed for Infants
- A disruptive, life-saving solution for home monitoring and management of lung fluid congestion in heart failure patients
- 4D Printing of Human Vascularized Cardiac Patches and Hearts for Regenerative Medicine
- Underground Emergency Hospital at Alrov Rehabilitation Tower
